Evidence map›Paper›PMID 38071720›Full record

Observational studyAnnals of surgical oncology2024

Association Between RAS/BRAF Mutations and Complete Response Following Total Neoadjuvant Therapy in Patients with Rectal Cancer: A Prospective Multicentered Study.

Sergei Bedrikovetski, Luke Traeger, Tracy Fitzsimmons, Timothy J Price, Andrew R Ruszkiewicz, Ryash Vather, Tarik Sammour

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Annals of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Pan-ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer.United European gastroenterology journal · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Sergei BedrikovetskiColorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, Australia. sergei.bedrikovetski@gmail.com.ORCID http://orcid.org/0000-0001-9330-625X
Luke TraegerColorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, Australia.
Tracy FitzsimmonsColorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, Australia.
Timothy J PriceDepartment of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, SA, Australia.
Andrew R RuszkiewiczCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
Ryash VatherDiscipline of Surgery, Faculty of Health and Medical Sciences, School of Medicine, University of Adelaide, Adelaide, SA, Australia.
Tarik SammourColorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, SA, Australia.
Royal Adelaide Hospital · AUSouth Australia Pathology · AUQueen Elizabeth Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe impact of RAS/BRAF mutation on primary response rates after total neoadjuvant therapy (TNT) in patients with advanced rectal cancer is unclear. The aim of this study was to assess complete response rates after TNT according to RAS/BRAF mutation status.

methodsA prospective observational study was performed in patients with rectal cancer who underwent TNT with curative intent at three South Australian hospitals between 2019 and 2023. Patients were classified according to their mutation status: mutant RAS/BRAF (mutRAS) or wild-type RAS/BRAF (wtRAS). The primary endpoint was overall complete response (oCR) rate, defined as the proportion of patients who achieved clinical complete response (cCR) and/or pathological complete response (pCR).

resultsOf the 150 patients eligible for inclusion, 80 patients with RAS/BRAF status available were identified. Of these, 43 (53.8%) patients were classified as mutRAS and 37 (46.3%) patients as wtRAS. Patients with mutRAS had significantly lower cCR and oCR rates after TNT than patients with wtRAS (14% vs. 37.8%, p = 0.014; 11.6% vs. 43.2%, p = 0.001, respectively). There was no significant difference in pCR rate between the groups. Of the 80 rectal cancer patients tested, 35 (43.8%) had metastatic disease (M1). There was no significant difference in complete M1 response rates between the groups (17.6% vs. 38.9%, p = 0.254).

conclusionRAS/BRAF mutations negatively impact primary tumor response rates after TNT in patients with advanced rectal cancer. Large-scale national studies are needed to determine whether RAS/BRAF status could be used to select optimal oncologic therapy in rectal cancer patients.

Indexed as

Proto-Oncogene Proteins B-rafRectal NeoplasmsAustraliaHumansMutationNeoadjuvant TherapyPathologic Complete ResponseProspective StudiesBRAF protein, humanProto-Oncogene Proteins B-rafBRAFKeywordsKRASNRASRASRectal cancerTotal neoadjuvant therapy

Identifiers

PMID38071720
OpenAlexW4389521372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.